<DOC>
	<DOCNO>NCT01142869</DOCNO>
	<brief_summary>The aim prospective , observational , multicenter , post-marketing study evaluate safety efficacy Cetuximab ( Erbitux ) combination platinum base chemotherapy , first line therapy recurrent/ metastatic squamous cell carcinoma head neck ( SCCHN ) . A total 100 subject SCCHN recruit 20 centre across India .</brief_summary>
	<brief_title>An Observational Study Evaluate Safety Efficacy Cetuximab Combination With Platinum-based Chemotherapy First-line Treatment Recurrent Metastatic Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The study inclusion criterion per label patient metastatic/recurrent SCCHN approve India Health Authorities , i.e. , `` Cetuximab indicate treatment patient squamous cell cancer head neck combination platinumbased chemotherapy recurrent and/or metastatic disease . '' For platinumbased chemotherapy , related product label approve India Health Authorities also follow strictly term patient eligibility . Patients know severe ( grade 3 4 ; National Cancer InstituteCommon Toxicity Criteria [ NCICTC ] ) hypersensitivity reaction Cetuximab contraindicate Cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Carcinoma , Squamous Cell</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Neoplasms , Squamous Cell</keyword>
</DOC>